Literature DB >> 32476827

Temporary remission of autoimmune pulmonary alveolar proteinosis after infectious episodes.

Takehiko Kobayashi1, Toru Arai2, Masaki Hirose2, Tomomi Homma2, Akiko Matsumuro2, Chikatoshi Sugimoto2, Masanori Kitaichi3,4, Masanori Akira5, Yoshikazu Inoue2.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare disease of unknown aetiology. Although resolution occurs in about 30% of autoimmune PAP (APAP) cases, its pathogenesis is not yet sufficiently understood. Two APAP cases at our institute showed remission following infectious episodes. Case 1: a 40-year-old female APAP patient suffered from herpes encephalitis and was treated with an antiviral drug. Her symptoms and radiological results resolved within two months of her recovery from the encephalitis. Case 2: A 53-year-old male current-smoker APAP patient was admitted for pneumonia. After treatment with antibiotics, his radiological results and symptoms improved. He experienced a similar resolution of APAP after another infectious episode two years later. Remission of APAP may occur following viral or bacterial infection. We hypothesise that remission of APAP is triggered by the induction of granulocyte-macrophage colony-stimulating factor (GM-CSF) following viral or bacterial infection. Further studies of APAP remission, and especially of the effects of GM-CSF induction, are needed. (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 85-90). Copyright:
© 2017.

Entities:  

Keywords:  infection; pulmonary alveolar proteinosis; remission

Year:  2017        PMID: 32476827      PMCID: PMC7170115          DOI: 10.36141/svdld.v34i1.5086

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  24 in total

1.  Pulmonary alveolar proteinosis.

Authors:  S H ROSEN; B CASTLEMAN; A A LIEBOW
Journal:  N Engl J Med       Date:  1958-06-05       Impact factor: 91.245

2.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

3.  Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy.

Authors:  R M Barraclough; A J Gillies
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

Review 4.  Opportunistic infections in patients with pulmonary alveolar proteinosis.

Authors:  Ankit D Punatar; Shimon Kusne; Janis E Blair; M Teresa Seville; Holenarasipur R Vikram
Journal:  J Infect       Date:  2012-04-04       Impact factor: 6.072

5.  Pulmonary alveolar proteinosis associated with psoriasis and complicated by mycobacterial infection: successful treatment with granulocyte-macrophage colony stimulating factor after a partial response to whole lung lavage.

Authors:  Jamalul Azizi Abdul Rahman; Yuben P Moodley; Martin J Phillips
Journal:  Respirology       Date:  2004-08       Impact factor: 6.424

6.  Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis.

Authors:  M S Kavuru; E J Sullivan; R Piccin; M J Thomassen; J K Stoller
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

7.  Isolation of mycobacteria in patients with pulmonary alveolar proteinosis.

Authors:  L A Witty; V F Tapson; C A Piantadosi
Journal:  Medicine (Baltimore)       Date:  1994-03       Impact factor: 1.889

Review 8.  Pulmonary alveolar proteinosis: progress in the first 44 years.

Authors:  John F Seymour; Jeffrey J Presneill
Journal:  Am J Respir Crit Care Med       Date:  2002-07-15       Impact factor: 21.405

9.  Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis.

Authors:  Takuro Sakagami; Kanji Uchida; Takuji Suzuki; Brenna C Carey; Robert E Wood; Susan E Wert; Jeffrey A Whitsett; Bruce C Trapnell; Maurizio Luisetti
Journal:  N Engl J Med       Date:  2009-12-31       Impact factor: 91.245

10.  Autoimmune Pulmonary Alveolar Proteinosis Following Pulmonary Aspergillosis.

Authors:  Toru Arai; Yoshikazu Inoue; Masanori Akira; Koh Nakata; Masanori Kitaichi
Journal:  Intern Med       Date:  2015-12-15       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.